Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Pharmaceutics|February 25, 2023
Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle-Mimetic Nanovesicles Loaded with ChemotherapeuticsSergey Brezgin, Anastasiya Kostyusheva, Natalia Ponomareva, et al.Pharmaceutics|May 25, 2024
Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic EnvironmentNatalia Ponomareva, Sergey Brezgin, Ivan Karandashov, et al.British Journal of Haematology|February 14, 2021
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocolGrigory Tsaur, Alexander Popov, Tatiana Riger, et al.Cancers|December 9, 2023
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALLAlexander Popov, Günter Henze, Julia Roumiantseva, et al.British Journal of Haematology|December 31, 2021
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangementsAlexander Popov, Grigory Tsaur, Tatiana Verzhbitskaya, et al.Molecular Therapy. Nucleic Acids|March 3, 2023
Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9Dmitry Kostyushev, Anastasiya Kostyusheva, Sergey Brezgin, et al.Journal of Cancer Research and Clinical Oncology|September 28, 2022
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 studyAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.Pediatric Blood & Cancer|March 28, 2023
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurementAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.Cancer Medicine|April 23, 2024
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocolAlexander Popov, Guenter Henze, Grigory Tsaur, et al.Pediatric Blood & Cancer|June 17, 2022
Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocolAlexander Popov, Grigory Tsaur, Zhan Permikin, et al.Pageof 4